This course has expired. View available courses.
Oncology, Haematology
Highlights from the IMW Meeting
Tune in to this comprehensive discussion between haematologists Dr. David Routledge and Dr. Isaac Goncalves of the Peter MacCallum Cancer Centre, Victoria, as they detail the highlights of the 18th International Myeloma Workshop held in September 2021 in Vienna, Austria. The International Myeloma Workshop is the defining meeting in myeloma with a focus on both […]
DURATION
45 min
PROFESSION
Specialist
# OF CREDITS
0
ACCREDITATION
Unaccredited
EXPIRY DATE
2022-10-25
Tune in to this comprehensive discussion between haematologists Dr. David Routledge and Dr. Isaac Goncalves of the Peter MacCallum Cancer Centre, Victoria, as they detail the highlights of the 18th International Myeloma Workshop held in September 2021 in Vienna, Austria.
The International Myeloma Workshop is the defining meeting in myeloma with a focus on both the preclinical and the clinical aspects of haematology in 2021.
Drs. Routledge and Goncalves review risk adapted therapies in myeloma, with a particular focus on high-risk features in myelomas. Particular focus is given to papers presented covering 2 clinically-challenging patient sub-groups:
- transplant ineligible patients (MAIA study – triplet therapy)
- fit patients with ultra-high risk features (OPTIMUM/MUKnine trial – 5 first-line agents)
The ‘hot topic’ at IMW 2021 was COVID-19 and myeloma. Our experts review and analyse key findings post-vaccination of patients with myeloma.
This program is supported by an independent and unrestricted educational grant by Amgen
Faculty
Dr. David Routledge, BSc (Hons), MBChB, MSc, PGCert, MRCP UK, FRCPath UK, RACP
Dr. Isaac Goncalves, MBBS, FRACP, PhD, FRCPA